Equity and debt offerings as they're announced. https://quantisnow.com/news/offerings en-us Fri, 24 Apr 2026 02:05:22 GMT /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, April 23, 2026 /CNW/ - The Toronto-Dominion Bank ("TD" or the "Bank") today announced a domestic public offering of C$1 billion of medium term notes (non-viability contingent capital (NVCC)) constituting subordinated indebtedness of the Bank (the "Notes").  The Notes will be issued and sold through a dealer syndicate led by TD Securities Inc. The Notes are expected to be issued on April 30, 2026 and will bear interest at a fixed rate of 4.208% per annum (paid semi-annually) until June 16, 2031, and at Daily Compounded CORRA plus 1.27% thereafter (paid quarterly) until maturity on June 16, 2036. https://quantisnow.com/insight/td-bank-group-to-issue-nvcc-subordinated-debentures-6513257 https://quantisnow.com/insight/td-bank-group-to-issue-nvcc-subordinated-debentures-6513257 Thu, 23 Apr 2026 22:17:00 GMT -- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease (FSCD) ---- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 ---- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Hal https://quantisnow.com/insight/agomab-reports-full-year-2025-financial-results-and-confirms-2026-6513253 https://quantisnow.com/insight/agomab-reports-full-year-2025-financial-results-and-confirms-2026-6513253 Thu, 23 Apr 2026 22:14:17 GMT Jefferies Financial Group Inc. (NYSE:JEF) ("JFG", "we" or "our") today announced the pricing of its public offering of $1.1 billion aggregate principal amount of 5.125% Senior Notes due 2031 (the "Notes") with an effective yield of 5.304%, maturing April 28, 2031. The offering is expected to settle on April 28, 2026, subject to the satisfaction of customary closing conditions. JFG intends to use the net proceeds of the offering for general corporate purposes. Jefferies LLC served as sole global co-ordinator and joint book-runner for the offering of the Notes, SMBC Nikko Securities America, Inc. served as joint book-runner, BNY Mellon Capital Markets, LLC, Citigroup Global Markets Inc. and https://quantisnow.com/insight/jefferies-financial-group-inc-announces-pricing-of-1100000000-5125-senior-6513229 https://quantisnow.com/insight/jefferies-financial-group-inc-announces-pricing-of-1100000000-5125-senior-6513229 Thu, 23 Apr 2026 21:44:00 GMT THE WOODLANDS, Texas, April 23, 2026 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality" or the "Company") (NASDAQ:TH), one of North America's largest providers of vertically-integrated modular accommodations and value-added hospitality services, today announced that it has closed its previously announced underwritten, secondary offering (the "Offering") of 8,050,000 shares of its common stock, par value $0.0001 per share (the "Common Stock"), held by Arrow Holdings S.à r.l. and MFA Global S.à r.l. (collectively, the "Selling Stockholders"), entities controlled by TDR Capital LLP, acting in its capacity as investment fund manager, at a price to the public of $14.00 per share, incl https://quantisnow.com/insight/target-hospitality-announces-closing-of-secondary-offering-and-full-exercise-6513017 https://quantisnow.com/insight/target-hospitality-announces-closing-of-secondary-offering-and-full-exercise-6513017 Thu, 23 Apr 2026 21:00:00 GMT BERRYVILLE, Va., April 23, 2026 /PRNewswire/ -- Eagle Financial Services, Inc. (NASDAQ:EFSI) (the "Company"), the holding company for Bank of Clarke, announced its first quarter 2026 results. Also, on April 23, 2026, the Board of Directors announced a quarterly common stock cash dividend of $0.31 per common share, payable on May 15, 2026, to shareholders of record on May 4, 2026. The following table presents selected financial performance highlights for the periods indicated: Three Months EndedMarch 31,December 31,March 31,202620252025(Dollars in thousands, except per share data https://quantisnow.com/insight/eagle-financial-services-inc-announces-2026-first-quarter-financial-results-6512897 https://quantisnow.com/insight/eagle-financial-services-inc-announces-2026-first-quarter-financial-results-6512897 Thu, 23 Apr 2026 20:35:00 GMT Lifezone Metals Limited (NYSE:LZM) announced today the closing of its previously announced1 share purchase agreement with institutional investors for the sale of 5,700,000 ordinary shares at a price of $4.40 per share. The offering raised approximately $25 million in gross proceeds to the Company, before deducting placement agent fees and offering-related expenses. The net proceeds of this offering will be used for exploration activities in Burundi and Tanzania, the PGM Recycling Project, conducting Hydromet research and development at Simulus Laboratory, and for other general corporate and working capital purposes, including financing costs. Current pre-FID, early-stage work, and project https://quantisnow.com/insight/lifezone-metals-announces-closing-of-25-million-registered-direct-offering-6512805 https://quantisnow.com/insight/lifezone-metals-announces-closing-of-25-million-registered-direct-offering-6512805 Thu, 23 Apr 2026 20:30:00 GMT SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closing of its underwritten public offering of $373.8 million of shares of its common stock. Nektar sold 4,062,500 shares of common stock in the offering, which includes 529,891 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The shares of common stock were sold at a public offering price of $92.00 per share. The gross proceeds to Nektar from the offering were approximately $373.8 million, before deducting underwritin https://quantisnow.com/insight/nektar-therapeutics-announces-closing-of-3738-million-public-offering-including-6512611 https://quantisnow.com/insight/nektar-therapeutics-announces-closing-of-3738-million-public-offering-including-6512611 Thu, 23 Apr 2026 20:15:00 GMT TSXV: ITR; NYSE American: ITRG www.integraresources.comVANCOUVER, BC, April 23, 2026 /CNW/ - Integra Resources Corp. ("Integra" or the "Company") (TSXV:ITR) (NYSE:ITRG) is pleased to provide an interim operational update for the first quarter ended March 31, 2026 (the "first quarter 2026" or "Q1 2026") highlighting continued operational momentum, record mining rates, and a strengthened balance sheet. The Company plans to release its first quarter 2026 financial results after market close on Monday May 11, 2026, followed by a conference call hosted by senior management on Tuesday https://quantisnow.com/insight/integra-announces-first-quarter-production-results-from-the-florida-canyon-6512396 https://quantisnow.com/insight/integra-announces-first-quarter-production-results-from-the-florida-canyon-6512396 Thu, 23 Apr 2026 20:05:00 GMT ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics" or the "Company"), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 16,129,033 shares of its common stock at an offering price of $0.31 per share of common stock. Additionally, in a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 16,129,033 shares of common stock at an exercise price https://quantisnow.com/insight/outlook-therapeutics-announces-closing-of-50-million-registered-direct-offering-6512344 https://quantisnow.com/insight/outlook-therapeutics-announces-closing-of-50-million-registered-direct-offering-6512344 Thu, 23 Apr 2026 20:05:00 GMT New York, New York, April 23, 2026 (GLOBE NEWSWIRE) -- ESH Acquisition Corp. (the "Company") (NASDAQ:ESHA) announced today that the Company received a notice (the "Deficiency Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "Form 10-K"), and therefore no longer complies with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.  The Deficiency Notice stated that the Company has 60 calendar days to submit a plan to re https://quantisnow.com/insight/esh-acquisition-corp-announces-receipt-of-nasdaq-deficiency-letter-redemption-6512281 https://quantisnow.com/insight/esh-acquisition-corp-announces-receipt-of-nasdaq-deficiency-letter-redemption-6512281 Thu, 23 Apr 2026 20:01:00 GMT VANCOUVER, BC, April 23, 2026 /CNW/ - Cascadia Minerals Ltd. ("Cascadia") (TSXV:CAM) (OTCQB:CAMNF) is pleased to announce that it has closed its previously announced non-brokered private placement (the "Offering") with Agnico Eagle Mines Limited ("Agnico Eagle") (TSX:AEM) (NYSE:AEM) and certain other arms' length subscribers (the "Flow-Through Participants"). Unless otherwise indicated, all dollar amounts are stated in Canadian dollars. The Offering consisted of the issuance and sale of:19,315,300 units of Cascadia (the "Subscribed Units") to Agnico Eagle at a price of $0.26 per https://quantisnow.com/insight/cascadia-announces-closing-of-equity-investment-6512248 https://quantisnow.com/insight/cascadia-announces-closing-of-equity-investment-6512248 Thu, 23 Apr 2026 19:34:00 GMT Venture Global, Inc. (("Venture Global", NYSE:VG) announced today that its subsidiary, Venture Global Calcasieu Pass, LLC ("VGCP") has closed an offering of $750,000,000 aggregate principal amount of 6.000% senior secured notes due 2036 (the "Notes"). The Notes will mature on May 1, 2036. VGCP used the net proceeds from the offering, together with cash on hand and proceeds received from certain hedge terminations, for the prepayment, in full, of VGCP's outstanding term loans, and to pay fees and expenses in connection with the offering. The Notes are guaranteed by TransCameron Pipeline, LLC (VGCP's affiliate). The Notes are secured on a pari passu basis by a first-priority security intere https://quantisnow.com/insight/venture-global-announces-closing-of-750000000-senior-secured-notes-by-6512178 https://quantisnow.com/insight/venture-global-announces-closing-of-750000000-senior-secured-notes-by-6512178 Thu, 23 Apr 2026 17:47:00 GMT AUSTIN, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Virtuix Inc. (NASDAQ:VTIX), a leading developer of full-body virtual reality systems, today announced that it will hold a virtual investor webinar on Friday, May 8, 2026, at 11:00 a.m. Eastern Time. Virtuix Chief Executive Officer Jan Goetgeluk will give an overview of the company's business and growth strategy, and discuss the company's recent commercial successes and developments, including its accelerating traction in the defense industry. Mr. Goetgeluk will be joined by Mr. David Allan, Virtuix's President and Chief Operating Officer, and Ms. Lauren Premo, Virtuix's Chief Marketing Officer. A question-and-answer session will follow. T https://quantisnow.com/insight/virtuix-to-host-virtual-investor-webinar-on-friday-may-8-6511875 https://quantisnow.com/insight/virtuix-to-host-virtual-investor-webinar-on-friday-may-8-6511875 Thu, 23 Apr 2026 12:47:00 GMT NEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the pricing of an underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15M investment from a fundamental institutional investor with support from a large existing shareholder. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other e https://quantisnow.com/insight/lucid-diagnostics-announces-18-million-underwritten-offering-of-common-stock-6511815 https://quantisnow.com/insight/lucid-diagnostics-announces-18-million-underwritten-offering-of-common-stock-6511815 Thu, 23 Apr 2026 12:30:00 GMT RICHMOND, Va., April 23, 2026 (GLOBE NEWSWIRE) -- ARKO Corp. (NASDAQ:ARKO) (the "Company"), a Fortune 500 company and one of the largest convenience store operators in the United States, today announced that the Company will host a conference call on Thursday, May 7, 2026 at 9:00 a.m. Eastern Time to discuss its financial results for the first quarter ended March 31, 2026. ARKO Corp.'s management team will host the conference call, followed by a question-and-answer period. The Company will provide its financial results in a press release prior to the call. Date: Thursday, May 7, 2026Time: 9:00 a.m. Eastern TimeToll-free dial-in number: (877) 605-1792 International dial-in number: (201) 6 https://quantisnow.com/insight/arko-to-report-first-quarter-2026-financial-results-on-may-6511782 https://quantisnow.com/insight/arko-to-report-first-quarter-2026-financial-results-on-may-6511782 Thu, 23 Apr 2026 12:30:00 GMT LSI Industries Inc. (NASDAQ:LYTS, "LSI" or the "Company")) a leading U.S. based manufacturer of commercial lighting and display solutions, today reported results for the fiscal 2026 third quarter ended March 31, 2026. FISCAL 2026 THIRD QUARTER RESULTS Completed the acquisition of Royston Group on March 24, 2026 Net Sales of $150.5 million, +14% y/y; net sales excluding Royston +9% y/y Net Income $2.1 million; Adjusted Net Income $9.6 million, +52% y/y Diluted EPS of $0.06; Adjusted Diluted EPS of $0.28 EBITDA of $7.5 million; Adjusted EBITDA of $15.0 million, +34% y/y Ratio of net debt to TTM proforma Adjusted EBITDA 2.7x During the fiscal third quarter, LSI reported https://quantisnow.com/insight/lsi-industries-reports-fiscal-2026-third-quarter-results-and-declares-6511444 https://quantisnow.com/insight/lsi-industries-reports-fiscal-2026-third-quarter-results-and-declares-6511444 Thu, 23 Apr 2026 11:00:00 GMT Consolidated Net Sales Decline of 3.3% GAAP Diluted Loss Per Share of $2.41 Adjusted Diluted EPS(1) of $0.83 Cash Flow from Operations of $111.3 Million; Free Cash Flow(1)(2) of $103.1 Million   Initiates Fiscal 2027 Outlook: Consolidated Net Sales of $1.751-$1.822 Billion GAAP Diluted EPS of $3.57-$4.18; Adjusted Diluted EPS(1) of $3.25-$3.75 Adjusted EBITDA(1) of $190-$197 Million; Free Cash Flow(1)(2) of $85-$100 Million Helen of Troy Limited (NASDAQ:HELE) reported results for the three-month period ended February 28, 2026 and provided its outlook for fiscal 2027. Executive Summary – Fourth Quarter of Fiscal 2026 Compared to Fiscal 2025 Consolidated net sales revenue of $470.0 https://quantisnow.com/insight/helen-of-troy-reports-fourth-quarter-fiscal-2026-results-6511389 https://quantisnow.com/insight/helen-of-troy-reports-fourth-quarter-fiscal-2026-results-6511389 Thu, 23 Apr 2026 10:45:00 GMT STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that an abstract has been accepted for publication at the upcoming 2026 ASCO Annual Meeting along with a corresponding poster presentation. The 2026 ASCO Annual Meeting will be held from May 28 to June 2, 2026. The full text of the abstract and poster will be available on June 1, 2026, the day of the presentation. CEO Snehal Patel commented, " We look forward to https://quantisnow.com/insight/greenwich-lifesciences-announces-acceptance-of-abstract-at-asco-2026-6511215 https://quantisnow.com/insight/greenwich-lifesciences-announces-acceptance-of-abstract-at-asco-2026-6511215 Thu, 23 Apr 2026 10:00:00 GMT L3Harris Technologies (NYSE:LHX) has closed a $1 billion strategic investment from the Department of War (DoW) in its Missile Solutions (MSL) business, which it will use to expand and modernize facilities, accelerate research and development, and increase production capacity for critical national security technologies. The investment from the DoW is in the form of a convertible preferred security of the MSL business, which will convert into common equity upon an initial public offering (IPO). In addition, the DoW will receive certain warrants to purchase common stock in MSL. As previously announced, L3Harris intends to pursue an IPO of MSL in the second half of 2026, pending market condit https://quantisnow.com/insight/l3harris-closes-1b-investment-from-department-of-war-in-missile-6511211 https://quantisnow.com/insight/l3harris-closes-1b-investment-from-department-of-war-in-missile-6511211 Thu, 23 Apr 2026 10:00:00 GMT GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 64,250,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors that so choose, pre-funded warrants to purchase an aggregate of up to 10,750,000 shares of its common stock and accompanying common stock warrants to purchase an aggregat https://quantisnow.com/insight/altimmune-announces-pricing-of-225-million-oversubscribed-public-offering-of-6511183 https://quantisnow.com/insight/altimmune-announces-pricing-of-225-million-oversubscribed-public-offering-of-6511183 Thu, 23 Apr 2026 03:25:00 GMT STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely https://quantisnow.com/insight/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-6510835 https://quantisnow.com/insight/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-6510835 Wed, 22 Apr 2026 21:00:00 GMT GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase an equivalent number of shares of its common stock (or pre-funded warrants in lieu thereof), and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying common stock warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). All of the shares, pre-funded warrants https://quantisnow.com/insight/altimmune-announces-proposed-underwritten-public-offering-of-securities-6510535 https://quantisnow.com/insight/altimmune-announces-proposed-underwritten-public-offering-of-securities-6510535 Wed, 22 Apr 2026 20:19:41 GMT AXT, Inc. (NASDAQ:AXTI) ("AXT" or the "Company"), a leading manufacturer of compound semiconductor wafer substrates, announced today the closing of its underwritten public offering of 8,560,311 shares of common stock at a price to the public of $64.25 per share. The Company received total gross proceeds of approximately $550 million, before deducting the underwriting discounts and commissions and other offering expenses. In addition, the Company granted the underwriter a 30-day option to purchase up to 1,284,046 additional shares of common stock at the public offering price, less the underwriting discounts (the "Overallotment Option"). If the Overallotment Option is fully exercised, the Com https://quantisnow.com/insight/axt-announces-closing-of-public-offering-of-common-stock-6510237 https://quantisnow.com/insight/axt-announces-closing-of-public-offering-of-common-stock-6510237 Wed, 22 Apr 2026 20:05:00 GMT - Expands Committed Investment Pipeline to More than $125 Million - - Increases 2026 Full Year Earnings Guidance - NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Getty Realty Corp. (NYSE:GTY) ("Getty" or the "Company"), a net lease REIT focused on convenience and automotive retail real estate, announced today its financial and operating results for the quarter ended March 31, 2026. First Quarter 2026 Highlights Net earnings: $0.43 per shareFunds From Operations ("FFO"): $0.69 per shareAdjusted Funds From Operations ("AFFO"): $0.63 per shareInvested $30.3 million across 29 properties at an 8.0% initial cash yieldExtended leases totaling $11.3 million, or 5.0% of annualized base rent (ABR) https://quantisnow.com/insight/getty-realty-corp-announces-first-quarter-2026-results-6510208 https://quantisnow.com/insight/getty-realty-corp-announces-first-quarter-2026-results-6510208 Wed, 22 Apr 2026 20:05:00 GMT SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) a clinical stage development company based in San Diego and focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Hendrick Scholl, Chief Medical Officer, will present at the Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference (dbVIC) on April 28th, 2026. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors. Details of the presentation are as follows: DATE: April 28th TIME: 9:00 a.m. ET REGISTER HERE This will be a live, interactive o https://quantisnow.com/insight/belite-bio-to-present-at-the-deutsche-bank-american-depositary-6509698 https://quantisnow.com/insight/belite-bio-to-present-at-the-deutsche-bank-american-depositary-6509698 Wed, 22 Apr 2026 12:35:00 GMT NEW YORK, April 22, 2026 /PRNewswire/ -- Kerrisdale Capital Management, LLC and Steamboat Capital Partners, LLC today sent a letter to the CEO and Board of Directors of ACM Research, Inc.  The full text of the letter follows:April 22, 2026David H. WangChief Executive OfficerACM Research, Inc.42307 Osgood Road, Suite IFremont, CA  94539cc: Board of DirectorsDear David,Kerrisdale Capital Management, LLC, Steamboat Capital Partners LLC and our respective affiliates collectively own or advise entities owning approximately 600,000 shares of ACM Research, Inc. We are excited to hear that management is taking preliminary steps to pursue a Hong Kong share listing, per your Form 8-K filed with the Se https://quantisnow.com/insight/kerrisdale-and-steamboat-send-letter-to-acm-research-inc-6509685 https://quantisnow.com/insight/kerrisdale-and-steamboat-send-letter-to-acm-research-inc-6509685 Wed, 22 Apr 2026 12:30:00 GMT CHARLOTTE, N.C., April 22, 2026 /PRNewswire/ -- Honeywell (NASDAQ:HON) today announced that Quantinuum LLC ("Quantinuum" or the "Company"), which is majority owned by Honeywell, confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission (the "SEC") on February 17, 2026, relating to the proposed initial public offering of Quantinuum's common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process. https://quantisnow.com/insight/honeywell-announces-quantinuums-confidential-submission-of-draft-registration-statement-for-6509679 https://quantisnow.com/insight/honeywell-announces-quantinuums-confidential-submission-of-draft-registration-statement-for-6509679 Wed, 22 Apr 2026 12:30:00 GMT ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics" or the "Company"), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company will issue unregis https://quantisnow.com/insight/outlook-therapeutics-announces-50-million-registered-direct-offering-priced-at-the-market-6509655 https://quantisnow.com/insight/outlook-therapeutics-announces-50-million-registered-direct-offering-priced-at-the-market-6509655 Wed, 22 Apr 2026 12:30:00 GMT Lifezone Metals Limited (NYSE:LZM) announced today that it has entered into a share purchase agreement with fundamental institutional investors for the sale of 5,700,000 ordinary shares at a price of $4.40 per share. Gross proceeds to the Company are expected to be approximately $25 million, excluding placement agent fees and offering-related expenses. The net proceeds of this offering will be used for exploration activities in Burundi and Tanzania, the PGM Recycling Project, conducting Hydromet research and development at Simulus Laboratory, and for other general corporate and working capital purposes, including financing costs. The offering is expected to close on or about April 23, 202 https://quantisnow.com/insight/lifezone-metals-announces-pricing-of-25-million-registered-direct-offering-6509586 https://quantisnow.com/insight/lifezone-metals-announces-pricing-of-25-million-registered-direct-offering-6509586 Wed, 22 Apr 2026 12:01:00 GMT VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- General Fusion Inc. ("General Fusion" or the "Company"), a leader in the global race to commercialize fusion energy, today announced that its executive leadership team plans to host a presentation at the Company's Analyst Day on Wednesday, April 29, 2026. The event is part of General Fusion's ongoing process toward becoming the first publicly traded pure-play fusion energy company. General Fusion previously announced its plans to go public through a business combination (the transactions contemplated by the business combination, collectively, the "Proposed Business Combination") with Spring Valley Acquisition Corp. III (NASDAQ https://quantisnow.com/insight/general-fusion-to-host-analyst-day-on-april-29-as-6509557 https://quantisnow.com/insight/general-fusion-to-host-analyst-day-on-april-29-as-6509557 Wed, 22 Apr 2026 12:00:00 GMT   Hadron Energy, Inc. ("Hadron" or "Company"), a developer of advanced nuclear microreactors, announced the submission of its Principal Design Criteria (PDC) White Paper for Hadron's Halo Modular Microreactor (Halo MMR) to the U.S. Nuclear Regulatory Commission (NRC) as part of the formal pre-application engagement process under 10 CFR Part 52 (Project No. 99902144). The submission, dated April 10, 2026, formalizes the technical and safety framework that will govern all future license applications for the Halo MMR, including a Manufacturing License (ML) and a combined Construction Permit and Operating License (COL). It builds upon the Company's prior regulatory filings including its Quali https://quantisnow.com/insight/hadron-energy-submits-principal-design-criteria-whitepaper-to-us-nuclear-6509540 https://quantisnow.com/insight/hadron-energy-submits-principal-design-criteria-whitepaper-to-us-nuclear-6509540 Wed, 22 Apr 2026 12:00:00 GMT SCOTTSDALE, Ariz., April 22, 2026 (GLOBE NEWSWIRE) -- Caliber (NASDAQ:CWD), a diversified real estate and digital asset management platform, today announced that it continues to execute on its multi-market Hyatt Studios development platform, advancing three hospitality projects across high-conviction markets: Steamboat Springs, CO; Riverwalk/Scottsdale, AZ; and Georgetown, TX. The first project in Steamboat Springs closed acquisition and construction financing in April 2026 and is expected to break ground during the second quarter of 2026. The platform represents a focused effort to capitalize on supply-constrained markets and growing demand for extended-stay hospitality. The announcement https://quantisnow.com/insight/caliber-advances-hyatt-studios-development-platform-across-three-high-growth-markets-6509387 https://quantisnow.com/insight/caliber-advances-hyatt-studios-development-platform-across-three-high-growth-markets-6509387 Wed, 22 Apr 2026 11:15:00 GMT NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Keel Infrastructure Corp. (NASDAQ/TSX:KEEL) ("Keel Infrastructure" or "Keel"), a North American digital and energy infrastructure company, today closed the previously announced sale of its 70 MW site in Paso Pe, Paraguay. After customary closing adjustments, total proceeds from the sale were approximately $13 million, from an originally agreed price of up to $30 million. The revision reflects the deterioration in Bitcoin mining economics and broader macro factors. Under the terms of the share purchase agreement, Sympatheia Power Fund led the acquisition from Keel and its affiliates of 100% of the shares of the single purpose subsidiary. "This s https://quantisnow.com/insight/keel-infrastructure-announces-closing-of-paso-pe-sale-6509348 https://quantisnow.com/insight/keel-infrastructure-announces-closing-of-paso-pe-sale-6509348 Wed, 22 Apr 2026 11:00:00 GMT New Campaign Reflects Commitment to Delivering ExcellencePRINCETON, N.J. and MIAMI, April 22, 2026 /PRNewswire/ -- Miami International Holdings, Inc. (MIAX®) (NYSE:MIAX), a technology-driven leader in building and operating regulated financial markets across multiple asset classes, today announced its new nationwide advertising campaign, "Excellence in Every Exchange." The broad-reaching campaign marks a significant milestone in MIAX's marketing strategy to expand brand awareness and deepen engagement across the broader financial ecosystem following its August 2025 initial public offering. https://quantisnow.com/insight/miax-launches-excellence-in-every-exchange-nationwide-advertising-campaign-6509285 https://quantisnow.com/insight/miax-launches-excellence-in-every-exchange-nationwide-advertising-campaign-6509285 Wed, 22 Apr 2026 10:45:00 GMT SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions a https://quantisnow.com/insight/maze-therapeutics-announces-150-million-registered-offering-6509144 https://quantisnow.com/insight/maze-therapeutics-announces-150-million-registered-offering-6509144 Wed, 22 Apr 2026 04:09:44 GMT SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $325 million of shares of its common stock. Nektar is selling 3,532,609 shares of common stock at a public offering price of $92.00 per share. The gross proceeds to Nektar from the offering are expected to be approximately $325 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Nektar has granted the underwriters a 30-day option to purchase up to an additional https://quantisnow.com/insight/nektar-therapeutics-announces-pricing-of-upsized-325-million-public-offering-6509135 https://quantisnow.com/insight/nektar-therapeutics-announces-pricing-of-upsized-325-million-public-offering-6509135 Wed, 22 Apr 2026 01:30:00 GMT ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in person at McCormick Place in Chicago, IL, and online, May 29 – June 2, 2026. With three abstracts selected for rapid oral presentations and three abstrac https://quantisnow.com/insight/ascentage-pharma-to-present-data-from-multiple-trials-including-three-6509096 https://quantisnow.com/insight/ascentage-pharma-to-present-data-from-multiple-trials-including-three-6509096 Wed, 22 Apr 2026 00:00:00 GMT This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025 to its short form base shelf prospectus dated October 31, 2025.San Antonio, Texas--(Newsfile Corp. - April 21, 2026) - HIVE Digital Technologies Ltd. (TSXV:HIVE) (NASDAQ:HIVE) (BVC: HIVECO) (the "Company" or "HIVE"), today announced that HIVE Bermuda 2026 Ltd., its wholly-owned subsidiary (the "Issuer") has closed its private offering (the "Offering") of US$115 million aggregate principal amount of 0% exchangeable senior notes due 2031 (the "Notes") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "S https://quantisnow.com/insight/hive-digital-announces-closing-of-private-offering-of-us115-million-6509093 https://quantisnow.com/insight/hive-digital-announces-closing-of-private-offering-of-us115-million-6509093 Tue, 21 Apr 2026 23:47:00 GMT Total Revenue growth of 13% year-on-year Adjusted EBITDAR Margin of 25% Operating Margin of 11% Liquidity to LTM Revenue ratio at 23% MEXICO CITY, April 21, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroméxico S.A.B. de C.V. (NYSE:AERO, BMV:AERO, "Aeroméxico" or the "Company")) today reported unaudited consolidated financial results for the three months ended March 31, 2026 ("1Q26"). These results are based on information available to us as of the date of this earnings release and are not a comprehensive statement of our financial results for the period presented. The Company has used the U.S. dollar, its functional currency, as the presentation currency for its consolidated financial statements. https://quantisnow.com/insight/aeromxico-reports-unaudited-first-quarter-2026-results-6509019 https://quantisnow.com/insight/aeromxico-reports-unaudited-first-quarter-2026-results-6509019 Tue, 21 Apr 2026 22:00:00 GMT NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Society Pass Incorporated (NASDAQ:SOPA) (the "Company"), Southeast Asia's (SEA) next generation e-commerce ecosystem announced the received notice of delinquency letter from Nasdaq. On April 16, 2026, Society Pass Incorporated (the "Company") received a delinquency notification letter (the "Notice") from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of the Company's failure to timely file its Annual Report on Form 10-K for the period ended December 31, 2025 (the "Filing"). The Listing Rule requires https://quantisnow.com/insight/society-pass-incorporated-nasdaq-sopa-nasdaq-delinquency-notification-letter-the-6508904 https://quantisnow.com/insight/society-pass-incorporated-nasdaq-sopa-nasdaq-delinquency-notification-letter-the-6508904 Tue, 21 Apr 2026 21:10:00 GMT New York, April 21, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a note offering (the "Offering") of $45 million for its client Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI), (the "Company", "Faraday Future" or "FF"), a California-based global Embodied AI (EAI) ecosystem company. Under the terms of the Offering, $15 million was funded directly to the Company in connection with a first note and $30 million was deposited into a controlled deposit account in connection with a second note (together with the first note, the https://quantisnow.com/insight/univest-securities-llc-announces-closing-of-45-million-note-offering-6508826 https://quantisnow.com/insight/univest-securities-llc-announces-closing-of-45-million-note-offering-6508826 Tue, 21 Apr 2026 21:00:00 GMT New York, April 21, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a $40,000,000 equity line facility with an initial tranche of $10,000,000 (the "Offering") for its client PMGC Holdings, Inc. (NASDAQ:ELAB) (the "Company"), a diversified holding company executing a targeted roll-up strategy in U.S.-based precision manufacturing. The purchase agreement provides for an equity line of credit under which the Company agreed to issue and sell to the Investor, upon the terms and conditions set forth in the purchase agreement: one or mor https://quantisnow.com/insight/univest-securities-llc-announces-a-40-million-equity-line-facility-6508821 https://quantisnow.com/insight/univest-securities-llc-announces-a-40-million-equity-line-facility-6508821 Tue, 21 Apr 2026 21:00:00 GMT WESTBURY, N.Y., April 21, 2026 /PRNewswire/ -- Kensington Capital Acquisition Corp. VI (NYSE:KCAC) (the "Company") announced that, commencing April 24, 2026, holders of the units sold in the Company's initial public offering of 23,000,000 units, completed on March 5, 2026, may elect to separately trade the Class 1 redeemable warrants included in the units. Those units not separated will continue to trade on the New York Stock Exchange (the "NYSE") under the symbol "KCAC.U," and the Class 1 redeemable warrants that are separated and the resulting new units consisting of one Class A ordinary share and three-quarters of one Class 2 redeemable warrant will trade on the NYSE under the symbols "KC https://quantisnow.com/insight/kensington-capital-acquisition-corp-vi-announces-the-separate-trading-of-6508786 https://quantisnow.com/insight/kensington-capital-acquisition-corp-vi-announces-the-separate-trading-of-6508786 Tue, 21 Apr 2026 20:49:00 GMT Strong Financial Performance and Successful Follow on Equity offering Highlight First Quarter Results Financial Highlights Diluted earnings per share of $2.92 for the first quarter of 2026, compared to $2.77 for the prior linked quarter and $1.45 for the prior year period. Net interest income for the first quarter of 2026 was $85.9 million, an increase of $19.0 million or 28.3%, compared to the prior year period. The net interest margin for the first quarter of 2026 was 4.08%, an increase of 40 basis points compared to 3.68% for the prior year period. Annualized return on average equity ("ROAE") of 15.4% and annualized return on average tangible common equity1 ("ROATCE") of 15 https://quantisnow.com/insight/metropolitan-bank-holding-corp-reports-first-quarter-2026-results-6508346 https://quantisnow.com/insight/metropolitan-bank-holding-corp-reports-first-quarter-2026-results-6508346 Tue, 21 Apr 2026 20:05:00 GMT Surf Air Mobility Inc. (NYSE:SRFM) (the "Company"), a leading regional air mobility platform, announced today the closing of its previously announced registered direct offering for the purchase and sale of 13,318,181 shares of common stock at a purchase price of $1.10 per share by certain institutional investors and the purchase and sale of 257,353 shares of common stock at a purchase price of $1.36 per share, the official New York Stock Exchange closing price for the common stock on April 17, 2026, by certain directors and officers of the Company (collectively, the "Offering"). The gross proceeds to the Company from the offering were approximately $15 million, before deducting financial https://quantisnow.com/insight/surf-air-mobility-announces-closing-of-15-million-registered-direct-6508329 https://quantisnow.com/insight/surf-air-mobility-announces-closing-of-15-million-registered-direct-6508329 Tue, 21 Apr 2026 20:05:00 GMT CAPE CANAVERAL, Fla., April 21, 2026 /PRNewswire/ -- Sidus Space, Inc. (NASDAQ:SIDU) ("Sidus" or the "Company"), an innovative space and defense technology company, today announced the closing of its previously announced best-efforts offering of 13,453,700 shares of its Class A common stock (or pre-funded warrants ("Pre-funded Warrants") in lieu thereof). Each share of Class A common stock (or Pre-funded Warrant) was sold at an offering price of $4.35 per share (inclusive of the Pre-funded Warrant exercise price) for gross proceeds of approximately $58.5 million, before deducting the placement agent's fees and offering expenses. All of the shares of Class A common stock and Pre-funded Warran https://quantisnow.com/insight/sidus-space-announces-closing-of-offering-6508254 https://quantisnow.com/insight/sidus-space-announces-closing-of-offering-6508254 Tue, 21 Apr 2026 20:00:00 GMT SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("the Company"), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the closing of its previously announced underwritten secondary public offering of 3,100,000 shares of the Company's common stock by Dr. Yoshiyuki Aikawa (the "Selling Stockholder") at the public offering price of $3.25 per share. The proceeds from the offering to the Selling Stockholder were approximately $10.1 million, before deducting underwriting discounts and commissions. The Company did not sell any shares of its common stock in the offering. The Selling Stockholder received all of the pro https://quantisnow.com/insight/sbc-medical-announces-closing-of-previously-announced-secondary-public-offering-6508247 https://quantisnow.com/insight/sbc-medical-announces-closing-of-previously-announced-secondary-public-offering-6508247 Tue, 21 Apr 2026 20:00:00 GMT PlusAI business has strong momentum with growing revenue and multiple operational milestones expected in 2026; ​​Existing investors support next capital raise PlusAI and Churchill Capital Corp IX (NASDAQ:CCIX) today announced the termination of the previously announced business combination due to market conditions. PlusAI continues to demonstrate significant commercial momentum and remains strongly positioned for long-term growth. Existing PlusAI investors support PlusAI's continued growth and commercialization plans, reflecting their confidence in the company's business strength and technology leadership. "Our business has significant momentum. With strong expected revenue in 2026 an https://quantisnow.com/insight/plusai-and-churchill-capital-corp-ix-terminate-business-combination-6508186 https://quantisnow.com/insight/plusai-and-churchill-capital-corp-ix-terminate-business-combination-6508186 Tue, 21 Apr 2026 18:00:00 GMT The Era of Dumb Batteries Is Over. Electra, the AI "Brain for Batteries,"™ is going public. More Range. Longer Life. Higher Performance and ROI Across Grid Storage, EVs, Drones, and Robotics — All Delivered in Software, Without Adding a Single Cell. The control plane for Every Battery on Earth: Monitoring, Optimization, and Control as software: "Our AI is not watching the battery. It is running it." NASA Spinoff and NVIDIA Inception Program recognized. Backed by global strategic investors (Stellantis, BlackBerry, and Ferrari Family Investments). The standard that the electrified economy is converging on. In January 2025, a Tesla Cybertruck wrapped in Electra's logo drove from Bost https://quantisnow.com/insight/electra-vehicles-inc-and-iron-horse-acquisition-ii-corp-nasdaq-6507979 https://quantisnow.com/insight/electra-vehicles-inc-and-iron-horse-acquisition-ii-corp-nasdaq-6507979 Tue, 21 Apr 2026 13:25:00 GMT GREENVILLE, S.C., April 21, 2026 /PRNewswire/ -- Southern First Bancshares, Inc. (NASDAQ:SFST) (Southern First), today announced its financial results for the three months ended March 31, 2026. Strong loan growth and continued margin expansion drove year-over-year net interest income growth of 29%. Net income was $9.9 million and diluted earnings per share was $1.19, representing a $0.54, or 83%, increase over the first quarter of 2025, and relatively unchanged from the fourth quarter of 2025. Return on average assets was 0.91%, up 39 basis points over the first quarter of last year, and tangible common equity to assets was 8.29%, up 41 basis points from the first quarter of 2025. Net charge https://quantisnow.com/insight/southern-first-reports-first-quarter-2026-results-6507844 https://quantisnow.com/insight/southern-first-reports-first-quarter-2026-results-6507844 Tue, 21 Apr 2026 12:30:00 GMT